Pfizer Inc. is weighing a sale of the pumps and devices business it acquired in last year’s purchase of Hospira Inc., people with knowledge of the matter said.
The U.S. drugmaker could fetch about $2 billion from a potential sale, the people said, asking not to be identified as the details are private. The process is at a very early stage and the details could change, the people said. Pfizer may also choose not to sell the Hospira unit at this time, they said.
The U.S. drugmaker could fetch about $2 billion from a potential sale, the people said, asking not to be identified as the details are private. The process is at a very early stage and the details could change, the people said. Pfizer may also choose not to sell the Hospira unit at this time, they said.
